GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
5 Phases
Drug Approvals
126
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
Clinical Trials
Distribution across different clinical trial phases (3327 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT07168356
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT07150091
- Locations
- π°π·
GSK Investigational Site, Ulsan, South Korea
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT07150104
- Locations
- πΈπͺ
GSK Investigational Site, Falun, Sweden
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
- Conditions
- Influenza, Human
- Interventions
- Biological: Flu mRNA (Formulation A)Biological: Flu mRNA (Formulation B)Combination Product: Comparator 2Combination Product: Comparator 1Combination Product: Comparator 3
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 770
- Registration Number
- NCT07121192
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
- Conditions
- Neoplasms, Endometrial
- Interventions
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT07108270
- Prev
- 1
- 2
- 3
- 4
- 5
- 712
- Next
News
ALX Oncology Appoints Barbara Klencke as Interim Chief Medical Officer to Advance Cancer Pipeline
ALX Oncology has appointed Dr. Barbara Klencke as Interim Chief Medical Officer, replacing Dr. Alan Sandler who will return to the company's Board of Directors.
Hengrui Licenses Heart Disease Drug HRS-1893 to Braveheart Bio for $65M Upfront, Potential $1B+ Total
Jiangsu Hengrui Pharmaceuticals has licensed its selective myosin blocker HRS-1893 to Delaware-based startup Braveheart Bio for $65 million upfront plus potential milestone payments exceeding $1 billion.
SCYNEXIS Presents Promising Data on SCY-247 Against Drug-Resistant Fungal Infections at TIMM-12 Congress
SCYNEXIS will present six studies at TIMM-12 demonstrating SCY-247's broad-spectrum antifungal activity against drug-resistant Candida auris, C. glabrata, and Aspergillus species.
ArcaScience Secures $7M to Accelerate AI-Driven Drug Safety Evaluation Platform
ArcaScience raised $7 million in seed funding to expand its AI platform that transforms drug benefit-risk assessments from months-long processes to seconds-long computations.
GSK Receives FDA Orphan Drug Designation for Autosomal Dominant Polycystic Kidney Disease Treatment
GSK received FDA Orphan Drug Designation for its investigational treatment of autosomal dominant polycystic kidney disease (ADPKD), a rare genetic disorder affecting approximately 600,000 people in the U.S.
BioVersys Receives EMA Orphan Designation for Novel Tuberculosis Combination Therapy
BioVersys AG received European Medicines Agency orphan designation for alpibectir combined with ethionamide to treat tuberculosis, following successful Phase 2a proof of concept trials.
Comprehensive Clinical Trials Review Reveals Global Lennox-Gastaut Syndrome Research Landscape
A new comprehensive report analyzes the global clinical trials landscape for Lennox-Gastaut Syndrome, providing critical data on trial numbers, enrollment figures, and regional distribution across G7 and E7 nations.
GSK Launches First PD-1 Immunotherapy and PARP Inhibitor for Gynecological Cancers in India
GlaxoSmithKline has introduced Jemperli and Zejula therapies in India, marking the company's entry into the oncology segment with treatments for gynecological cancers.
Invivyd Raises $57.5 Million to Advance Monoclonal Antibody Pipeline Targeting RSV, Measles, and Long COVID
Invivyd completed a $57.5 million public offering in August 2025 to accelerate development of monoclonal antibody candidates for respiratory syncytial virus, measles, and Long COVID treatments.
Dynavax's Z-1018 Shingles Vaccine Matches GSK's Shingrix Efficacy with Superior Tolerability in Phase I/II Trial
Dynavax's investigational shingles vaccine Z-1018 demonstrated comparable immune responses to GSK's Shingrix, achieving a 100% humoral vaccine response rate versus 96.9% for Shingrix in adults aged 50-69 years.